<DOC>
	<DOCNO>NCT00185614</DOCNO>
	<brief_summary>To determine toxicity feasibility mixed chimera allogeneic hematopoietic cell transplant multiple myeloma ; prepare vaccinate patient allogenic dendritic cell vaccination follow mixed chimera allogeneic hematopoietic cell transplant</brief_summary>
	<brief_title>Mixed Chimera Allo Transplantation Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Hematologic Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Multiple myeloma . Eligible patient may early relapse disease . Patients must Stage IIIII disease progression initial treatment Stage I disease . Age less equal 70 year . No prior therapy would preclude use lowdose total body irradiation . Patients must pathology review diagnosis confirm Stanford University Medical Center . Patients smolder multiple myeloma , monoclonal gammopathy unknown significance , primary amyloidosis exclude study . Patients must Karnofsky performance status great 70 % . DLCO &gt; =60 % predict . ALT AST must &lt; 2X normal . Total bilirubin le 2 mg/dl . Serum creatinine &lt; 2.0 24hour creatinine clearance &gt; =60 ml/min . Patients must HIV negative . Pregnant lactate woman eligible participate . Patients must provide sign , informed consent . Patients must HLAidentical sibling donor . Severe psychological medical illness Patients undergone prior allogeneic hematopoietic cell transplantation eligible study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2011</verification_date>
</DOC>